文献速递淋巴瘤造血干细胞移植与细胞治疗

克隆性造血对接受ASCT的淋巴瘤患者的临床影响:一项全国性人群队列研究

Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study.
PubMed 文献 · Leukemia · 2020-03-20

该研究在丹麦全国范围纳入892例接受干细胞采集的淋巴瘤患者,其中565例有采集样本可用于二代测序检测CHIP,中位随访9.1年。计划立即ASCT的患者中25.5%(112/440)携带至少一种CHIP突变;CHIP整体与总生存无显著关联,但DNA修复通路基因(PPM1D、TP53、RAD21、BRCC3)突变者总生存显著较差。

要点

  • 计划立即ASCT的淋巴瘤患者中25.5%携带CHIP突变。
  • CHIP整体与总生存无显著关联,与既往单中心研究不同。
  • DNA修复通路基因突变者总生存显著较差,且治疗相关白血病和ICU入住率增加。

核心结论

  • 在基于人群的淋巴瘤ASCT队列中,CHIP整体与总生存无显著关联,但DNA修复通路基因突变与显著较差的总生存相关。

研究设计与样本

  • 全国性人群队列研究,纳入丹麦所有移植中心892例接受干细胞采集的淋巴瘤患者,565例有采集样本行二代测序检测CHIP,中位随访9.1年。

主要发现

  • 计划立即ASCT的患者中25.5%(112/440)携带至少一种CHIP突变。
  • 多因素分析中CHIP整体与总生存无显著关联。
  • DNA修复通路基因(PPM1D、TP53、RAD21、BRCC3)突变者随访1年后总生存风险比2.79(95%CI 1.71-4.56;p<0.0001),多因素分析p=0.00067。
  • DNA修复通路基因突变者治疗相关白血病和重症监护入住率增加。
  • 未立即ASCT者中DNA修复通路基因突变亦与显著较差的总生存相关(p=0.003)。

临床怎么用

  • 对计划ASCT的淋巴瘤患者可考虑检测CHIP,尤其关注DNA修复通路基因突变以识别高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal hematopoiesis of indeterminate potential (CHIP) is suspected of being a risk factor for patients with cancer. This study aimed to assess the clinical consequences of CHIP in patients with lymphoma intended for high-dose chemotherapy and autologous stem-cell transplantation (ASCT) in a population-based setting. We identified 892 lymphoma patients who had undergone stem cell harvest at all transplant centers in Denmark. A total of 565 patients had an available harvest sample, which was analysed for CHIP by next-generation sequencing, and the median follow-up was 9.1 years. Of the patients who were intended for immediate ASCT, 25.5% (112/440) carried at least one CHIP mutation. In contrast to previous single-center studies CHIP was not associated with inferior overall survival (OS) in multivariate analyses. However, patients with mutations in genes of the DNA repair pathway (PPM1D, TP53, RAD21, BRCC3) had a significant inferior OS (HR after 1 year of follow-up 2.79, 95% confidence interval 1.71-4.56; p < 0.0001), which also was evident in multivariate analysis (p = 0.00067). These patients had also increased rates of therapy-related leukemia and admission to intensive care. Furthermore, in patients who did not undergo immediate ASCT, a significant inferior OS of individuals with DNA repair mutations was also identified (p = 0.003).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Husby S, Favero F, Nielsen C, et al. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia. 2020. PMID: 32203146. doi:10.1038/s41375-020-0795-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。